Home/Pipeline/PP2A Reactivator Program

PP2A Reactivator Program

Cancer

PreclinicalActive

Key Facts

Indication

Cancer

Phase

Preclinical

Status

Active

Company

Rappta Therapeutics

About Rappta Therapeutics

Rappta Therapeutics is a private, pre-revenue biotech founded in 2020, advancing a novel class of small molecule therapeutics designed to reactivate the PP2A tumor suppressor. Operating at the lead optimization to late preclinical stage, the company is pioneering a molecular glue approach to target PP2A, offering a new mechanism to combat cancer and potentially other diseases. With a team split between Finland and the US, Rappta is building a platform based on deep structural and biological insights into PP2A inactivation. The company's success hinges on validating this challenging but high-potential target and advancing its lead candidates into clinical development.

View full company profile

Therapeutic Areas

Oncology

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active